5-(4-carboxyphenyl)pyrazin-2(1H)-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-carboxyphenyl)pyrazin-2(1H)-one
• 英文别名: 4-(5-Hydroxypyrazin-2-yl)benzoic acid；4-(6-oxo-1H-pyrazin-3-yl)benzoic acid
• 化学式: C₁₁H₈N₂O₃
• 分子量: 216.196
• InChiKey: UXXJARVLKXYKAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(4-carboxyphenyl)pyrazin-2(1H)-one 以 甲醇 为溶剂， 生成 5-(4-methoxycarbonylphenyl)pyrazin-2(1H)-one
  参考文献：
  名称：

  US4632924

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 4-(5-aminopyrazin-2-yl)benzoate 在 硫酸 、 sodium nitrite 、 sodium hydroxide 、 水 作用下， 反应 0.5h， 以36%的产率得到5-(4-carboxyphenyl)pyrazin-2(1H)-one
  参考文献：
  名称：

  WO2008/51493

  摘要：

  公开号：

文献信息

• [EN] NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE<br/>[FR] NOUVEAU DERIVES DE 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE
  申请人：ASTRAZENECA AB

  公开号：WO2005065688A1

  公开（公告）日：2005-07-21

  The invention relates to heterocyclic derivatives of formula (I), wherein R2 is amino, a group OR4 or a group -Y-R5 where R4 is hydrogen or C1-4alkyl, Y is C1-4alkylene, R5 is hydrogen, halo, hydroxy, C1-2alkoxy, C1-2alkoxyC1-2alkoxyC1-4, or a group NR7R8 where R7 and R8 are independently selected from hydrogen, C1-2alkyl, hydroxyC1-2alkyl or alkoxyC1-2alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R1 is independently selected from halo, haloC1-2alkyl, hydroxy, oxo, amino, C1-2alkylamino or di-C1-2dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

  该发明涉及公式（I）的杂环衍生物，其中R2是氨基，羟基OR4基团或-Y-R5基团，其中R4是氢或C1-4烷基，Y是C1-4烷基烯，R5是氢，卤素，羟基，C1-2烷氧基，C1-2烷氧基C1-2烷氧基C1-4，或NR7R8基团，其中R7和R8分别选自氢，C1-2烷基，羟基C1-2烷基或烷氧基C1-2烷基，或R7和R8与它们连接的氮原子一起形成饱和的5-6成员杂环环，该环可选择性地包含额外的杂原子；n为一或二，每个R1独立选择自卤素，卤素C1-2烷基，羟基，羟基，氨基，C1-2烷基氨基或二C1-2二烷基氨基；或其药学上可接受的盐。这些化合物具有抗血栓和抗凝作用，因此在人类或动物治疗方法中有用。该发明还涉及制备这些杂环衍生物的方法，含有它们的药物组成物以及它们在制造用于产生抗血栓或抗凝作用的药物的制剂中的使用。
• Heterocyclic derivatives which inhibit factor Xa
  申请人：AstraZeneca AB

  公开号：US20040266759A1

  公开（公告）日：2004-12-30

  The invention relates to heterocyclic derivatives of formula (I), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect. 1

  本发明涉及公式（I）的杂环衍生物或其药学上可接受的盐，具有抗血栓和抗凝血性质，因此在人类或动物的治疗方法中有用。本发明还涉及制备杂环衍生物的过程，含有它们的制药组合物以及它们用于制造用于产生抗血栓或抗凝血效应的药物的用途。
• 5-(4-substituted)phenyl-2-pyrazinones
  申请人：SmithKline Beckman Corporation

  公开号：US04632924A1

  公开（公告）日：1986-12-30

  This invention relates to 5-(4-substituted)phenylpyrazinone compounds which have positive inotropic and vasodilator activity. One such compound is 5-(4-carboxamidophenyl)pyrazin-2(1H)-one.

  本发明涉及具有正性肌力作用和血管扩张作用的5-(4-取代)苯基吡嗪酮化合物。其中一种化合物是5-(4-羧酰胺基苯基)吡嗪-2(1H)-酮。
• Heteroaryl compounds, compositions thereof, and methods of treatment therewith
  申请人：Mortensen Deborah Sue

  公开号：US20090023724A1

  公开（公告）日：2009-01-22

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：其中R1，R2，L，X，Y，Z，Q，A和B的定义如下，包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症，炎症状况，免疫状况，代谢状况以及通过抑制激酶通路可治疗或预防的状况的方法，包括向需要治疗的患者中给予有效量的杂环芳基化合物。
• New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one
  申请人：Bratt Emma

  公开号：US20070135441A1

  公开（公告）日：2007-06-14

  The invention relates to heterocyclic derivatives of formula (I), wherein R 2 is amino, a group OR 4 or a group —Y—R 5 where R 4 is hydrogen or C 1-4 alkyl, Y is C 1-4 alkylene, R 5 is hydrogen, halo, hydroxy, C 1-2 alkoxy, C 1-2 alkoxyC 1-2 alkoxyC 1-4 , or a group NR 7 R 8 where R 7 and R 8 are independently selected from hydrogen, C 1-2 alkyl, hydroxyC 1-2 alkyl or alkoxyC 1-2 alkyl, or R 7 and R 8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R 1 is independently selected from halo, haloC 1-2 alkyl, hydroxy, oxo, amino C 1-2 alkylamino or di-C 1-2 dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

  本发明涉及式(I)的杂环衍生物，其中R2是氨基，OR4基团或-Y-R5基团，其中R4是氢或C1-4烷基，Y是C1-4亚烷基，R5是氢，卤素，羟基，C1-2烷氧基，C1-2烷氧基C1-2烷氧基C1-4，或NR7R8基团，其中R7和R8各自选自氢，C1-2烷基，羟基C1-2烷基或烷氧基C1-2烷基，或R7和R8与它们所连接的氮原子一起形成一个饱和的5-6元杂环环，其中可以含有一个额外的杂原子；n是1或2，每个R1独立地选自卤素，卤素C1-2烷基，羟基，氧代，氨基C1-2烷基氨基或二C1-2二烷基氨基；或其药学上可接受的盐。这些化合物具有抗血栓和抗凝作用，因此在人类或动物的治疗方法中有用。本发明还涉及制备这些杂环衍生物的方法，含有它们的药物组合物以及它们在制造用于产生抗血栓或抗凝效果的药物的制剂中的使用。